Oncology Brothers: Practice-Changing Cancer Discussions

Welcome to the Oncology Brothers podcast! In this episode we we deep into the complexities of venous thromboembolism (VTE) with Drs. Jennifer Vaughn and Nicolas Gallastegui Crestani from The Ohio State University. Join us as we explore real-life VTE scenarios, discussing both provoked and unprovoked events, treatment durations, and cancer-associated cases. We cover essential topics such as: •⁠  ⁠The workup for hypercoagulable states in young patients •⁠  ⁠Long-term anticoagulation strategies for high-risk individuals •⁠  ⁠The role of D-dimer and risk scores in decision-making •⁠  ⁠Management of anticoagulation in patients with cancer undergoing treatment •⁠  ⁠Rapid-fire scenarios including superficial vein thrombosis and portal vein thrombosis Whether you're a healthcare professional or simply interested in the latest in oncology and hematology, this episode is packed with valuable insights and practical guidance. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and tune in for more discussions on challenging cases, treatment algorithms, and expert insights in the field of oncology! #VTE #Anticoagulation #DOACs #Hematology #MedEd #OncologyBrothers #Thrombosis #Clots #DVT #PE

In this episode of the Oncology Brothers podcast, we are joined by Dr. Omid Hamid, a melanoma specialist from Cedars-Sinai, to explore the current treatment landscape of cutaneous melanoma. We covered a wide range of topics, including: •⁠  ⁠The standard of care for early-stage melanoma, including wide local excision and sentinel lymph node evaluation. •⁠  ⁠The role of adjuvant immunotherapy and BRAF/MEK inhibitors for high-risk patients. •⁠  ⁠Insights into neoadjuvant treatment options for resectable disease, including recent trial data from NADINA and SWOG S1808. •⁠  ⁠The importance of next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) in treatment planning and monitoring. •⁠  ⁠The evolving treatment paradigm for metastatic melanoma, including the use of dual checkpoint inhibitors and BRAF/MEK inhibitors. Join us as we discuss the latest advancements in melanoma treatment and the critical role of patient education and shared decision-making in oncology care. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes on treatment algorithms, new FDA approvals, and conference highlights! #Melanoma #Immunotherapy #BRAF #ctDNA #Neoadjuvant #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dive deep into the world of neuroendocrine tumors (NETs) with renowned expert Dr. Thor Halfdanarson from the Mayo Clinic. Join us as we explore: •⁠  ⁠The critical factors in diagnosing NETs, including origin, grade, histological features, and Ki-67. •⁠  ⁠The importance of differentiating between functional and non-functional tumors and how this impacts treatment decisions. •⁠  ⁠Dr. Halfdanarson's treatment paradigm, including the use of somatostatin analogs, radioligand therapy, and other targeted treatments. •⁠  ⁠Monitoring strategies for patients, including the role of imaging and tumor markers like 5-HIAA and chromogranin. •⁠  ⁠Insights into the evolving role of immunotherapy and next-generation sequencing in managing high-grade neuroendocrine carcinomas. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information and practical insights. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more discussions on cutting-edge cancer treatments and expert opinions in the field of oncology!

Dr. Balazs Halmos, a thoracic medical oncologist at Montefiore Einstein Cancer Center, joins the discussion on crucial findings from the World Conference on Lung Cancer 2025. He highlights the FLAURA2 trial, showcasing how osimertinib combined with chemotherapy enhances survival for EGFR-positive non-small cell lung cancer patients. Halmos delves into the HARMONi trial's unexpected results with a bi-specific antibody and the significance of ctDNA. He wraps up with insights on crizotinib's role in ALK-positive cases and the evolving landscape of precision oncology.

Dr. Mazyar Shadman, a leading expert in lymphoid malignancies at Fred Hutch Cancer Center, discusses the future of Chronic Lymphocytic Leukemia (CLL) treatment. He emphasizes the importance of shared decision-making and explores the timing for initiating treatment. Key topics include the choice between time-limited venetoclax regimens and continuous BTK inhibitors, the significance of minimal residual disease (MRD), and innovative strategies for managing relapsed CLL, such as Pirtobrutinib and CAR-T therapies.

Dr. Misty Shields, a medical oncologist at Indiana University specializing in small cell lung cancer, shares her insights on managing side effects from new treatments. She discusses the latest advancements from ASCO 2025, focusing on the treatment algorithm for patients with good performance status. Key points include common side effects of lurbinectedin and immunotherapy, strategies for managing hematologic toxicities, and the crucial role of supportive and palliative care in improving patient quality of life. Collaboration between community oncologists and academic centers is emphasized for optimal care.

Dr. Joshua Sabari, a medical oncologist at NYU Langone Cancer Center, shares his expertise on the groundbreaking approval of Zongertinib for HER2-mutated non-small cell lung cancer. He discusses the prevalence of HER2 mutations, revealing key study findings with impressive response rates and progression-free survival data. The podcast dives into the management of side effects, particularly diarrhea, and compares Zongertinib with trastuzumab deruxtecan in treatment settings. Dr. Sabari also explores future directions for HER2-targeted therapies.

Welcome to the Oncology Brothers podcast! In this episode, we kick off a three-part CME series focused on small cell lung cancer (SCLC). Joined by Dr. Hossein Borghaei, Chief of Thoracic Oncology at the Fox Chase Cancer Center. Together they dived into the evolving treatment landscape for SCLC, highlighting recent advancements and data from ASCO 2025. Episode Highlights: •⁠  ⁠Overview of the current standard of care for limited and extensive-stage SCLC. •⁠  ⁠Discussion on the role of concurrent chemoradiation therapy and the new standard of care involving immunotherapy. •⁠  ⁠Insights into the use of lurbinectedin in maintenance therapy and its impact on overall survival. •⁠  ⁠Exploration of the promising results from the DeLLphi study on tarlatamab, a bispecific antibody, and its implications for treatment. •⁠  ⁠The importance of patient selection and managing side effects in treatment decisions. Join us as we navigate the complexities of SCLC treatment and look forward to future advancements that may improve patient outcomes. Accreditation/Credit Designation Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/breaking-down-the-latest-clinical-data-for-first-line-maintenance-and-rr-sclc  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ #OncologyBrothers #SmallCellLungCancer #CME #ASCO2025 #LungCancer #Immunotherapy #CancerTreatment

In this episode of the Oncology Brothers podcast, Drs. Rohit & Rahul Gosain welcome Dr. Jacob Sands, a thoracic medical oncologist from the Dana-Farber Cancer Institute, to discuss the recent FDA approval of Dato-DXD (datopotamab deruxtecan) for previously treated EGFR-mutated non-small cell lung cancer (NSCLC). Key Topics: •⁠  ⁠Overview of Dato-DXd and its FDA approval •⁠  ⁠Mechanism of action and study design of the TROPION Lung trials •⁠  ⁠Efficacy and safety profile of Dato-DXd •⁠  ⁠Management of side effects and clinical pearls •⁠  ⁠Treatment sequencing for EGFR-mutated NSCLC Join us as we dive into the details of the TROPION Lung trials that led to this significant approval, the mechanism of action of Dato-DXd, and the implications for patients with various EGFR mutations.  Dr. Sands shared insights on the study design, efficacy, and tolerability of this new antibody-drug conjugate, as well as important clinical pearls for managing side effects such as stomatitis, dry eyes, and interstitial lung disease (ILD). We also explored the current treatment landscape for EGFR-mutated NSCLC, including the sequencing of therapies and the potential role of Dato-DXd in clinical practice. Tune in for an informative discussion that highlights the exciting advancements in oncology and the hope they bring to patients. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology!

Welcome to the Oncology Brothers podcast! In this episode, we continue our hematology series by diving deep into myelofibrosis (MF) with Dr. Raajit Rampal, an expert in myeloproliferative neoplasms from the Memorial Sloan Kettering Cancer Center. Join Drs. Rahul and Rohit Gosain as they discuss the latest updates in symptom management, emerging treatment combinations, and the importance of timely diagnosis and risk stratification for patients presenting with cytopenias and splenomegaly. Key topics covered in this episode include: • The initial workup and diagnostic criteria for myelofibrosis • The role of next-generation sequencing and bone marrow biopsy • Risk stratification using the IPSS and DIPSS scoring systems • First-line treatment options, including the four available JAK inhibitors: Ruxolitinib, Momelotinib, Fedratinib, and Pacritinib • Supportive care strategies for managing anemia and thrombocytopenia • The importance of clinical trials and early referral for transplant Tune in to gain valuable insights into the evolving treatment landscape for myelofibrosis and learn how community oncologists can effectively manage this complex disease. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes in our hematology series and check out our previous discussions!